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Abstract
Background: This study examined the association between race/ethnicity and health insurance
payer type with pediatric opioid and non-opioid ordering in an inpatient hospital setting.
Methods: Cross-sectional inpatient encounter data from June 2013 to June 2018 was retrieved
from a pediatric children's hospital in Southern California (N = 55,944) and statistical analyses
were performed to determine associations with opioid ordering.
Results: There was a significant main effect of race/ethnicity on opioid and non-opioid orders.
Physicians ordered significantly fewer opioid medications, but a greater number of non-opioid
medications, for non-Hispanic African American children than non-Hispanic Asian,
Hispanic/Latinx, and non-Hispanic White pediatric patients. There was also a main effect of
health insurance payer type on non-opioid orders. Patients with government-sponsored plans
(e.g., Medi-Cal, Medicare) received fewer non-opioid prescriptions compared with patients with
both HMO and PPO coverage. Additionally, there was a significant race/ethnicity by insurance
interaction on opioid orders. Non-Hispanic White patients with "other" insurance coverage
received the greatest number of opioid orders. In non-Hispanic African American patients,
children with PPO coverage received fewer opioids than those with government-sponsored and
HMO insurance. For non-Hispanic Asian patients, children with PPO were prescribed more
opioids than those with government-sponsored and HMO coverage.
Conclusion: Findings suggest that the relationship between race/ethnicity, insurance type, and
physician decisions opioid prescribing is complex and multifaceted. Given that consistency in
opioid prescribing should be seen regardless of patient background characteristics, future studies
should continue to assess and monitor unequitable differences in care.
Keywords. opioids; pediatric pain; electronic medical record; race and ethnicity; disparities
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Introduction
The unprecedented rates of opioid misuse and related deaths in the USA have
commanded the attention of public health professionals and governmental health agencies [1]. It
was reported that the death rate from abuse of opioids quadrupled between 1999 and 2010, a rate
which continues to increase and plague the nation [2,3]. In 2016 alone, the USA reported over
42,000 fatal opioid overdoses, signifying a 27% increase in mortality rate from 2015 [4]. Also, in
2016, 11.8 million Americans aged 12 and older misused opioids, with approximately 97.5% of
these Americans misusing prescription opioids specifically [4]. Although most studies and
responses to this crisis are adult-focused, there is a direct impact on the health of children. In
particular, pediatric opioid-related poisoning and deaths increased by 268% between 1999 and
2016, with the largest percent increase among children between ages 1 and 4 [5,6]. In addition,
16.2% of US emergency department visits among patients aged 13 through 17 were associated
with opioid use between 2006 and 2015 [7].
Although national prevalence estimates indicate that about 3.6% of youth between the
ages of 12 and 17 begin misusing prescription opioids each year [8], research focused on
assessing the predictors of legitimate opioid use in pediatric populations is scare. Markedly,
studies with adolescents support that opioid misuse is often preceded by a legitimate provider
prescription [9], suggesting that receiving an opioid prescription at a young age might represent a
risk factor for later misuse. In one nationally representative study, being prescribed an opioid
analgesic during adolescence was associated with a 33% increase in risk for later non-medical
opioid misuse in young adulthood [10]. Furthermore, a similar study of patients between the ages
of 13 and 21 also showed that patients prescribed opioids for pediatric postoperative pain had an
elevated risk of persistent opioid use 3 to 6 months after the surgical recovery period [11].

4
Given their high risk potential for misuse and abuse, current Centers for Disease Control
and Prevention (CDC) guidelines [12] highlight that opioids should not be considered the firstline therapy for treating pain and that non-pharmacologic therapy and non-opioid pharmacologic
therapy are preferred over opioid therapy. Specifically, non-opioids are shown to effectively
improve pain and patient outcomes while decreasing the risk of substance use and misuse in atrisk patients [13,14]. If opioids are prescribed, it is recommended that patients receive a
combination of opioids and non-opioid pharmacologic therapy, to synergistically improve the
analgesic potential [15,16]. Given this established link between legitimate opioid prescriptions
with later misuse [9] and persistent use [17], and the effectiveness of non-opioid medications in
treating pain [13,14], research focused on identifying distinct relationships between sociodemographic factors with both opioid and non-opioid prescribing for pediatric patients is needed
to understand prescribing inconsistencies and promote safe management for all patients,
regardless of their background characteristics.
Inequalities in access to healthcare are well-documented in adult patients, with research
supporting race-/ethnicity-based difference in physician opioid prescribing [18,19]. For example,
Pletcher, Kertesz, Kohn, and Gonzales [20] found that non-Hispanic White patients were the
most likely to receive opioid prescriptions, followed by Asian/other patients, Hispanic, and
African American patients. This study, however, may be limited with respect to our current,
ever-growing opioid epidemic, as it utilizes national data from 1993 to 2005 and a sample
composed of only 11% Hispanic and 2% Asian/other patients. Still, other studies consistently
show that non-Hispanic White adults receive significantly more opioid prescriptions than
African American adult patients [21–23], and a growing body of research supports a similar
trend in pediatric populations [19, 23–25]. For example, in a national study investigating
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pediatric emergency departments, White patients were prescribed opioid at an average rate of
8.11%, compared with a rate of 5.31% among non-White patients [7].
Similarly, research suggests that patient health insurance is related with opioid
prescribing [7, 26]. Patients with government-sponsored health insurance are shown to be less
likely to receive opioids compared with patients with commercial or private insurance coverage
[7, 26]. Governmental insurance plans are often used by families of low socioeconomic status
[27–30], whereas, commercial insurance plans are usually obtained through an employer,
indicating that these families have a member employed with benefits. Further, these commercial
plans, such as health maintenance organization (HMO) and preferred provider organization
(PPO), are typically more costly but provide better access to care [31]. Given that patient
healthcare insurance coverage represents a proxy of socioeconomic status [28–30], differences in
opioid prescribing based on insurance type might raise questions about the potential role of
provider bias [7]. As such, research elucidating differences in pain management can initiate
further work examining how to alleviate potential existing disparities.
Despite the established relationships between race/ethnicity and insurance payer type
with opioid prescribing shown in prior studies, the complex interaction effect between these two
sociodemographic variables and physician opioid prescription behaviors have not been assessed
simultaneously in one multivariable model. Given that research examining differences in
pediatric inpatient opioid use based on patient race/ethnicity and health insurance payer type is
crucial for promoting appropriate and safe pain management across diverse social and
demographic sectors, this study focused on identifying the multifaceted association of
race/ethnicity and health insurance payer type with both physician opioid and non-opioid
ordering for pediatric patients. Leveraging a large hospital dataset of pediatric inpatients,
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insurance-based differences in physician opioid and non-opioid ordering were examined, for
each racial/ethnic group, with hopes of understanding and helping to alleviate pain management
disparities in the pediatric hospital inpatient setting.
Materials and Methods
Data Source
Cross-sectional inpatient encounter data from June 2013 to June 2018 were retrieved
from a pediatric children's hospital in Southern California. Electronic medical record (EMR) data
were extracted from pediatric patients less than 18 years old that were admitted as inpatients.
Extracted EMR data include/d information on demographics (e.g., age, sex, race/ethnicity),
length of stay, maximum pain ratings, diagnosis, health insurance payer type, and physician
analgesic ordering. Records were de-identified, and patients were assigned a unique encounter
identifier, allowing medical record information to be linked. Data were managed using Amazon
Web Services [32], a tool that provides a protected cloud-based environment in which unlimited
amounts of EMR data can be computed, at scale, with quick speed.
Inclusion Criteria and Data Cleaning
The objective of this study was to assess differences in opioid ordering for children and
adolescents in pain, excluding cancer-associated chronic pain (for a similar criteria, see Chung et
al. [33] and Richardson et al. [34]). Specifically, information on neoplasms was extracted using
International Classification of Diseases, Ninth/Tenth revision, Clinical Modification codes C00
through D49. Patients with neoplasms were identified using the diagnosis codes and excluded
from the analyses. A final sample of pediatric patients with no history of neoplasm diagnoses
were selected to be included in the current study (N = 55,944).
Variables

7
Demographic information on age, sex, and race/ethnicity (Hispanic/Latinx, non-Hispanic
White, non-Hispanic African American, and non-Hispanic Asian) were extracted using the EMR
information for patients, excluding the oncology population. Patient insurance type was also
obtained and included government-sponsored plans (i.e., CalOptima, Medi-Cal, Medicare),
commercial HMO, commercial PPO, and "other" insurance types (e.g., CHAMPUS, self-pay,
EPO). In addition, clinical information on length of stay and the maximum pain intensity scores
of the patient during the encounter was retrieved and controlled for in all analyses (as done by
Ehwerhemuepha, Schultz, and Feaster [35]). More specifically, pain was assessed by providers
using several developmentally and situationally appropriate measurement tools (i.e., faces, legs,
activity, cry, and consolability scale [36]; faces pain scale [37]; numeric rating scale [38]; and
neonatal pain, agitation and sedation Scale [39]).
Patient medical diagnoses were also retrieved using the International Classification of
Diseases, Tenth Revision, and controlled for in the models (based on the procedures utilized in
several past studies with pediatric patients [40–43]). Specifically, the presence or absence of the
following conditions were included as covariates and controlled for in the study analyses:
bacterial and viral infection (A00-A99); diseases of the blood and blood-forming organs and
disorders involving immune mechanisms (D50-D89); endocrine, nutritional and metabolic
diseases (E00-E89); diseases of the nervous system (G00-G99); diseases of the circulatory
system (I00-I99); diseases of the respiratory system (J00-J99); diseases of the digestive system
(K00-K95); diseases of the musculoskeletal system and connective tissue (M00-M99); diseases
of the genitourinary system (N00-N99); congenital malformations, deformations and
chromosomal abnormalities (Q00-Q99); injury, poisoning and certain other consequences of
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external causes (S00-T88); and other diagnoses (H00-H59, L00-L99, O00-O9, P00-P96, Z00Z99).
Opioids considered include codeine, hydrocodone, hydromorphone, meperidine,
sufentanil, fentanyl, morphine, oxycodone, remifentanil, nalbuphine, methadone, and tramadol.
The outcome represented the total number of opioid medications across all opioid types that
providers ordered during hospitalization. Specifically, a sum of the total number of opioid
analgesic medications prescribed was computed as a sum score across all of the different
possible opioid types. Providers could have ordered more than one opioid, the same opioid
medication multiple times, multiple opioid orders, or a combination of the two. In addition,
information on the number of non-opioid analgesics (e.g., ibuprofen, acetaminophen, naproxen,
gabapentin, pregabalin, celecoxib, triptan) ordered was calculated in the same way.
Statistical Analysis
SPSS version 25 was used for statistical analyses. Two separate 4 (race/ethnicity:
Hispanic/Latinx; non-Hispanic White, non-Hispanic African American, non-Hispanic Asian) by
4 (insurance type: government-sponsored, commercial HMO, commercial PPO, other) betweensubjects analysis of covariance (ANCOVA) evaluated differences in the number of ordered
opioid and non-opioid analgesics based on race/ethnicity and insurance type. Age, sex, length of
stay, pain rating, medical diagnoses, and non-opioid analgesic medication prescription were
included as covariates. To investigate statistically significant interaction effects of race/ethnicity
and patient health insurance payer type, pair-wise comparisons using Fisher’s least significant
difference (LSD) t-tests were performed [44].
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Results
Descriptive information on all study variables are presented in Table 1. Separate 4 x 4
ANCOVA were performed to assess differences in physician opioid and non-opioid ordering
across patient race/ethnicity and health insurance groups.
Opioid Analgesic Orders
Univariate main effects attained statistical significance for race/ethnicity (Fig. 1), F(3,
55,911) = 4.72, p < 0.01, but not insurance type, F(3, 55,911) = 0.56, p = 0.64. Specifically, nonHispanic African American patients (M = 1.58, SE = 0.06, 95% CI [1.47, 1.70], n = 1816)
received significantly fewer opioid orders than Hispanic/Latinx (M = 1.72, SE = 0.02, 95% CI
[1.68, 1.75], n = 32,242), p = 0.034, and non-Hispanic White patients (M = 1.78 SE = 0.02, 95%
CI [1.74, 1.81], n = 16,214), p = 0.002.
Analyses also revealed a significant race/ethnicity by patient health insurance payer type
interaction, F(9, 55,911) = 5.59, p < 0.001. The significant interaction effect was decomposed by
comparing insurance differences within each racial/ethnic group (Fig. 2). Findings disclosed
significant omnibus insurance type differences for non-Hispanic White, F(3, 16,193) = 6.83, p <
0.001; non-Hispanic African American, F(3, 1795) = 3.73, p = 0.011; and non-Hispanic Asian
patients, F(3, 5651) = 7.36, p < 0.001. Statistically significant insurance payer type differences
were not found for Hispanic patients, F(3, 32,221) = 1.28, p = 0.281.
Among non-Hispanic White pediatric patients, children with "other" insurance plans (M
= 1.98, SE = 0.05, 95% CI [1.88, 2.09], n = 929) received more opioid orders than patients with
government-sponsored (M = 1.73, SE = 0.02, 95% CI [1.68, 1.77], n = 5093), p < 0.001; HMO
(M = 1.79, SE = 0.03, 95% CI [1.74, 1.84], n = 3711), p = 0.002; and PPO (M = 1.81, SE = 0.02,
95% CI [1.77, 1.85], n = 6,481), p = 0.003, insurance coverage. There was also a significant
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difference between government-sponsored plans (M = 1.73, SE = 0.02, 95% CI [1.68, 1.77], n =
5093) and PPO insurance (M = 1.81, SE = 0.02, 95% CI [1.77, 1.85], n = 6481), p = 0.009, for
non-Hispanic White children, with patients covered by PPO plans receiving a greater number of
opioid orders.
In exploring differences for non-Hispanic African American patients, findings revealed
that patients with PPO insurance (M = 1.49, SE = 0.08, 95% CI [1.34, 1.63], n = 348) received
significantly more opioids than patients with government-sponsored (M = 1.70, SE = 0.04, 95%
CI [1.62, 1.79], n = 1135), p = 0.013, and HMO (M = 1.82, SE = 0.09, 95% CI [1.65, 1.99], n =
266), p = 0.004, insurance types. For non-Hispanic Asian patients, those with PPO insurance (M
= 1.62, SE = 0.03, 95% CI [1.55, 1.69], n = 1992) received significantly more opioids than
patients with government-sponsored (M = 1.44, SE = 0.03, 95% CI [1.38, 1.50], n = 2398), p <
0.001, and HMO (M = 1.39, SE = 0.05, 95% CI [1.30, 1.66], n = 990), p < 0.001, insurance.
Non-Opioid Analgesic Orders
Univariate main effects on the outcome of non-opioid orders attained statistical
significance for race/ethnicity (Fig. 3), F(3, 55,911) = 5.63, p = 0.01, and insurance type, F(3,
55,911) = 4.26, p = 0.005 (Fig. 4). The race/ethnicity by patient insurance payer type interaction
was not significant, F(9, 55,911) = 1.62, p = 0.10 on the outcome of non-opioid orders. Thus,
simple effects were not explored.
An examination of the race/ethnicity main effect showed that non-Hispanic African
American patients (M = 2.18, SE = 0.04, 95% CI [2.10, 2.26], n = 1816) received significantly
more non-opioid orders than Hispanic/Latinx (M = 2.07, SE = 0.01, 95% CI [2.04, 2.09], n =
32,242), p = 0.007; non-Hispanic White (M = 2.03, SE = 0.01, 95% CI [2.01, 2.05], n = 16,214),
p < 0.001; and non-Hispanic Asian patients (M = 2.02, SE = 0.02, 95% CI [1.98, 2.06], n =
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5,672), p < 0.001. In addition, Hispanic/Latinx patients received more non-opioids than nonHispanic White patients, p = 0.045. Mean differences in patient insurance type were also
examined. Findings showed that patients with government-sponsored plans (M = 2.05, SE =
0.01, 95% CI [2.03, 2.07], n = 34,127) received fewer non-opioid orders compared with patients
with both commercial HMO coverage (M = 2.12, SE = 0.02, 95% CI [2.08, 2.16], n = 7924), p =
0.004, and PPO insurance (M = 2.10, SE = 0.02, 95% CI [2.07, 2.14], n = 11,982), p = 0.012.
Discussion
Accumulating evidence supports a link between provider opioid prescribing and
subsequent misuse and persistent use [9–11], fueling the current opioid epidemic in the USA [45,
46]. This observed trend has resulted in several discussions throughout the current healthcare
system regarding the overall safety of prescribing opioid medications, with the CDC
recommending that opioid use in pediatric patients is avoided when possible [12]. Given that the
prescription of opioids to pediatric patients is of high concern due to this group’s increased risk
of long-term side effects (e.g., addiction, misuse) [47], research focused on examining and
eliminating any potential prescribing differences based on patient characteristics is imperative. In
response, the current investigation aimed to compliment a growing body of research supporting
the existence of sociodemographic disparities in pediatric pain management, by testing possible
interaction effects between patient race/ethnicity and patient payer insurance type on opioid and
non-opioid physician ordering, with hopes of advancing pediatric health equity and encouraging
safe pain management across diverse groups.
Under the conditions of this study, providers ordered fewer opioid medications, but a
greater number of non-opioid analgesics, for non-Hispanic African American patients when
compared to Hispanic/Latinx and non-Hispanic White patients. This finding is consistent with a
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growing body of research demonstrating that African American pediatric patients are less likely
to be prescribed opioids compared with non-Hispanic White patients regardless of pain severity
[19, 23, 25]. Findings might suggest that African American pediatric inpatients are at risk of
suffering from pain disproportionally compared with patients with other background
characteristics. However, measuring the amount of opioids prescribed does not directly reflect
the quality of treatment a patient receives; likewise, this study is limited to identifying the
unequal use of opioids and cannot identify ethnic disparities in experienced pain. Still, it is welldocumented that race and ethnicity play a substantial role in the experience of pain in the adult
population, where African American and Hispanic patients report a lower tolerance for pain
compared with non-Hispanic White patients [48, 49]. Although there is a lack of research
examining this phenomenon in pediatric patients, providers should be cognizant of this potential
difference and practice thorough pain assessments when managing a diverse pediatric population
(e.g., utilizing observational methods in addition to self-report, using culturally validated
measures for pain) so that they are fully equipped with information to make an appropriate
treatment recommendation [50].
In contrast to prior studies supporting the association between patient insurance type and
opioid analgesic prescribing [7, 26], no significant differences in opioid ordering were shown
based on patient insurance type alone. Instead, there was a significant interaction of patient
race/ethnicity and insurance payer type on the number of opioids ordered by clinicians. Among
non-Hispanic White children, patients with "other" (e.g., self-pay) insurance coverage received
the greatest number of opioid orders. In contrast, for non-Hispanic African American patients,
children with PPO coverage received fewer opioids than those with government-sponsored and
HMO insurance payer types. For non-Hispanic Asian patients, children with PPO coverage were
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prescribed more opioids than those with government-sponsored and HMO coverage. Notably,
these findings did not hold for non-opioid medications suggesting that there may be something
specific about physician patterns of prescribing opioid medications.
Looking into the future of the opioid epidemic, the goal of the current work was to help
improve the safety of pediatric pain management, by elucidating an existing prescribing disparity
based on patient background characteristics. Findings support a complex and multifaceted
relationship between race/ethnicity, insurance type, and physician decisions about whether to
prescribe an opioid versus non-opioid medication to treat pain. Based on current standard of care
for managing moderate to severe pain in pediatric patients, consistency in opioid prescribing
across race/ethnicity should be seen. As such, additional studies may be required to fully
understand new strategies that are needed to improve the quality and equity of pediatric pain
management. Future efforts should continue to monitor quality care indicators associated with
unequitable differences in care.
Limitations
Findings should be considered in the context of several limitations. This investigation
sought to assess differences in physician ordering decisions and followed the assumption that
physicians ordered the appropriate dose for patients. Examining opioid orders as a proxy
measure of opioid prescribing represents a potential limitation. Specifically, the number of
opioids ordered might not have reflected the actual dosage administered to patients. Additional
research is needed to examine whether these findings replicate when assessing opioid
consumption as the outcome variable. Also, although legitimate opioid use has been identified as
a risk factor of later misuse, the relationship between opioid ordering and abuse/misuse was not
captured in this investigation. The relatively low effect sizes might also represent a limitation.
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Still, findings are practically and clinically significant, as they suggest potential clinician bias
that is likely outside of the prescriber's awareness. Also, similar effect sizes have been found in
other secondary studies examining substance use outcome [51].
It is also worth noting that California consists of a uniquely large Hispanic population—
39.3% of Californians identified as Hispanic in 2019 compared to 36.8% non-Hispanic White—
making these results difficult to compare with national data [52]. Additional studies may be
required to fully understand these results especially in relation to the proper management of pain
in pediatrics. In other words, additional research is needed to understand whether pain is being
managed properly using non-opioid alternatives in African Americans or if findings represent a
general trend in the disparity of healthcare that seem favorable to patients of this ethnic/racial
background. Still, this study represents an important starting point, and the results indicate that
there is need to consolidate evidence not only on the prescription of opioids but the misuse and
corresponding consequences.
Conclusion
Findings of the current investigation disclosed a unique interaction of race/ethnicity and
insurance type on physician opioid and non-opioid ordering, supporting that differences in opioid
prescribing are likely complex and multifaceted, and might be explained by several factors
including clinician uncertainty and misjudgments of patient pain [53], implicit provider bias [54],
and provider–patient communication and trust [55]. Still, additional studies are required to
provide full picture of the mechanisms driving both disparities and adverse opioid consequences
in pediatric populations. This study further strengthens the need to take care in the development
of interventions and health policies to tackle this epidemic. For example, such efforts might
focus on implementing hospital policies or programs that encourage physicians to reflect on their
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own cultural beliefs and biases, and could also center on empowering patients to adequately
report pain, while also educating parents about the importance of having an active voice involved
in their child's pain management [56]. However, interventions that do not consider racial/ethnic
and socioeconomic differences may be beneficial to one group while exacerbating the problem
within another. In the meantime, pediatric healthcare providers should be cognizant of complex
interplay between racial/ethnic and socioeconomic differences in the incidence and reporting of
pain and in the prescription of opioids and should work together to set out clear plans for
implementing evidence-based strategies for managing pain and reducing any existing health
disparities.
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Figure Captions

Fig 1. Significant main effect of patient race/ethnicity on the number of opioids prescribed per
patient visit. Values represented estimated marginal means controlling for all model covariates.
Error bars represent 95% confidence intervals. Brackets denote significant differences between
groups. *p < .05. **p < .01. ***p < .001.

Fig 2. Significant interaction of patient race/ethnicity and insurance payer type on the number of
opioids prescribed per patient visit. Values represented estimated marginal means controlling for
all model covariates. Error bars represent 95% confidence intervals. Brackets denote significant
differences between groups. *p < .05. **p < .01. ***p < .001.

Fig 3. Significant main effect of patient race/ethnicity on the number of non-opioids prescribed
per patient visit. Values represented estimated marginal means controlling for all model
covariates. Error bars represent 95% confidence intervals. Brackets denote significant differences
between groups. *p < .05. **p < .01. ***p < .001.

Fig 4. Significant main effect of patient insurance payer type on the number of non-opioids
prescribed per patient visit. Values represented estimated marginal means controlling for all
model covariates. Error bars represent 95% confidence intervals. Brackets denote significant
differences between groups. *p < .05. **p < .01. ***p < .001.

Table 1
Descriptive Statistics and Measure Summary Information (N = 55,944)
Age
Sex
Length of Stay
Maximum Pain Score
Race/Ethnicity

Patient Insurance Type

Medical Diagnosisa

Range
M (SD)
Male
Female
Range
M (SD)
Range
M (SD)
Hispanic/Latinx
Non-Hispanic White
Non-Hispanic African
American
Non-Hispanic Asian
Medicare/Medicaid/Medi-Cal
Commercial HMO
Commercial PPO
Other
Bacterial and viral infection
(A00-A99)
Diseases of the blood and
blood-forming organs and
disorders involving immune
mechanisms (D50-D89)
Endocrine, nutritional and
metabolic diseases (E00-E89)
Diseases of the nervous system
(G00-G99)
Diseases of the circulatory
system (I00-I99)
Diseases of the respiratory
system (J00-J99)
Diseases of the digestive
system (K00-K95)
Diseases of the musculoskeletal
system and connective tissue
(M00-M99)
Diseases of the genitourinary
system (N00-N99)
Congenital malformations,
deformations and chromosomal
abnormalities (Q00-Q99)

0 – 18 years
7.67 (5.60)
54.70%
45.30%
0 – 30 days
3.61 (4.52)
0 – 10
4.19 (3.10)
57.60%
29.00%
3.20%
10.10%
61.00%
14.20%
21.40%
3.40%
9.30%
12.20%
14.10%
18.30%
8.40%
21.90%
26.2%
8.40%
8.2%
18.6%

Injury, poisoning and certain
other consequences of external 10.4%
causes (S00-T88)
Other diagnoses (H00-H59,
L00-L99, O00-O9, P00-P96,
28.5%
Z00-Z99)
Range
0–9
Non-Opioid Analgesic
Orders
M (SD)
2.05 (1.25)
Range
0 – 11
Opioid Analgesic
Orders
M (SD)
1.74 (2.04)
a
Medical diagnosis frequencies represent the percentage of patients diagnosed with each
medical condition.

